Evidence map›Paper›PMID 38943220›Full record

ArticleActa neuropathologica communications2024

Retinal peri-arteriolar versus peri-venular amyloidosis, hippocampal atrophy, and cognitive impairment: exploratory trial.

Oana M Dumitrascu, Jonah Doustar, Dieu-Trang Fuchs, Yosef Koronyo, Dale S Sherman, Michelle Shizu Miller, Kenneth O Johnson, Roxana O Carare, Steven R Verdooner, Patrick D Lyden and 3 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cerebral Amyloid Deposition WithHuman brain mapping · 2025
    Article
  8. Review
  9. Article
  10. Review
  11. Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Oana M DumitrascuDepartments of Neurology, Mayo Clinic, AZ, 13400 E. Shea Blvd, Scottsdale, AZ, 85259, USA. dumitrascu.oana@mayo.edu.ORCID 0000-0003-2033-449X
Jonah DoustarDepartment of Neurosurgery, Cedars-Sinai Medical Center, Maxine Dunitz Neurosurgical Institute, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA.
Dieu-Trang FuchsDepartment of Neurosurgery, Cedars-Sinai Medical Center, Maxine Dunitz Neurosurgical Institute, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA.
Yosef KoronyoDepartment of Neurosurgery, Cedars-Sinai Medical Center, Maxine Dunitz Neurosurgical Institute, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA.
Dale S ShermanDepartment of Physical Medicine and Rehabilitation, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA.
Michelle Shizu MillerDepartment of Neurosurgery, Cedars-Sinai Medical Center, Maxine Dunitz Neurosurgical Institute, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA.
Kenneth O JohnsonNeuroVision Imaging LLC, 1395 Garden Hwy, Sacramento, CA, 95833, USA.
Roxana O CarareDepartment of Clinical Neuroanatomy, University of Southampton, University Road Southampton, Southampton, SO17 1BJ, UK.
Steven R VerdoonerNeuroVision Imaging LLC, 1395 Garden Hwy, Sacramento, CA, 95833, USA.
Patrick D LydenDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo St, Los Angeles, CA, 90033, USA.
Julie A SchneiderDepartment of Pathology, Department of Neurological Sciences, Alzheimer's Disease Research Center, Rush Medical College, Rush University, 600 S. Paulina St., Chicago, IL, 60612, USA.
Keith L BlackDepartment of Neurosurgery, Cedars-Sinai Medical Center, Maxine Dunitz Neurosurgical Institute, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA.
Maya Koronyo-HamaouiDepartment of Neurosurgery, Cedars-Sinai Medical Center, Maxine Dunitz Neurosurgical Institute, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA. maya.koronyo@csmc.edu.

Funding

Alzheimer's Disease Hallmark Pathology and Associated Inflammation in the RetinaR01AG055865 · NIA · CEDARS-SINAI MEDICAL CENTER · PI Maya Koronyo-Hamaoui · 2018 to 2026
$4.9M
The role of Chlamydia pneumoniae infection in Alzheimer's DiseaseR01AG075998 · NIA · CEDARS-SINAI MEDICAL CENTER · PI Timothy Robert Crother, Maya Koronyo-Hamaoui · 2021 to 2026
$3.7M
Retinal Imaging of Alzheimer's Disease PathologyR01AG056478 · NIA · CEDARS-SINAI MEDICAL CENTER · PI KORONYO-HAMAOUI, MAYA · 2017 to 2021
$2.5M
A noninvasive optical imaging of retinal amyloid beta deposits in AD patientsR41AG044897 · NIA · NEUROVISION IMAGING, LLC · PI KORONYO-HAMAOUI, MAYA · 2013 to 2013
$151k
NIA NIH HHS R01 AG055865NIA NIH HHS R01 AG056478NIA NIH HHS R01 AG075998NIA NIH HHS R41 AG044897
6 · The paper itself

Abstract

The relationship between amyloidosis and vasculature in cognitive impairment and Alzheimer's disease (AD) pathogenesis is increasingly acknowledged. We conducted a quantitative and topographic assessment of retinal perivascular amyloid plaque (AP) distribution in individuals with both normal and impaired cognition. Using a retrospective dataset of scanning laser ophthalmoscopy fluorescence images from twenty-eight subjects with varying cognitive states, we developed a novel image processing method to examine retinal peri-arteriolar and peri-venular curcumin-positive AP burden. We further correlated retinal perivascular amyloidosis with neuroimaging measures and neurocognitive scores. Our study unveiled that peri-arteriolar AP counts surpassed peri-venular counts throughout the entire cohort (P < 0.0001), irrespective of the primary, secondary, or tertiary vascular branch location, with a notable increase among cognitively impaired individuals. Moreover, secondary branch peri-venular AP count was elevated in the cognitively impaired (P < 0.01). Significantly, peri-venular AP count, particularly in secondary and tertiary venules, exhibited a strong correlation with clinical dementia rating, Montreal cognitive assessment score, hippocampal volume, and white matter hyperintensity count. In conclusion, our exploratory analysis detected greater peri-arteriolar versus peri-venular amyloidosis and a marked elevation of amyloid deposition in secondary branch peri-venular regions among cognitively impaired subjects. These findings underscore the potential feasibility of retinal perivascular amyloid imaging in predicting cognitive decline and AD progression. Larger longitudinal studies encompassing diverse populations and AD-biomarker confirmation are warranted to delineate the temporal-spatial dynamics of retinal perivascular amyloid deposition in cognitive impairment and the AD continuum.

Indexed as

AmyloidosisAtrophyCognitive DysfunctionHippocampusAgedAged, 80 and overFemaleHumansMaleMiddle AgedOphthalmoscopyPlaque, AmyloidRetinal DiseasesRetinal VesselsRetrospective StudiesAmyloid imagingCognitionHippocampal volumeNeurodegenerationPeri-arteriolarPerivascularPeri-venularRetina

Identifiers

PMID38943220
PMCPMC11212356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.